{
    "name": "trientine",
    "comment": "Rx",
    "other_names": [
        "Syprine",
        "Cuvrior"
    ],
    "classes": [
        "Copper Chelators"
    ],
    "source": "https://reference.medscape.com/drug/cuvrior-syprine-trientine-342888",
    "pregnancy": {
        "common": [
            "Available data on use of trientine for treatment of Wilson disease have not identified any drug-associated risks for major birth defects, miscarriages, or other adverse maternal or fetal outcomes ",
            "Monitor copper levels throughout pregnancy and use the minimum effective dose "
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Untreated Wilson disease or discontinuation of treatment during pregnancy may result in worsening neurological and hepatic symptoms, including rare reports of hepatic decompensation and liver failure ",
                    "Untreated Wilson disease may also increase risk of miscarriage in some symptomatic patients",
                    "Increased copper deposition in placenta and fetal liver may adversely impact fetus ",
                    "  ",
                    "  ",
                    "Trientine may chelate non-copper cations (eg, iron, calcium); maintain appropriate levels during pregnancy ",
                    "  ",
                    "  ",
                    "Chelator-induced copper deficiency may have adverse effects on fetus"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Oral administration in rats during organogenesis resulted in increased embryo-fetal loss at a dose lower than the maximum recommended dose (MDR) and produced fetal abnormalities at 2.7 x the MRD",
                    "Copper supplementation in pregnant rats produced a marked reduction in trientine-induced fetal abnormalities",
                    "Oral administration of trientine dihydrochloride to pregnant mice during organogenesis increased the percentage of mice with total embryofetal loss at ~4.3 x MDR and produced fetal abnormalities at ~1.1 x the MDR "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Published data are inconsistent regarding detection of trientine in breastmilk",
            "Available published literature have not reported drug-associated adverse effects in infants exposed to trientine through breastmilk "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to product or components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not indicated for cystinuria, RA (cf penicillamine) or biliary cirrhosis",
                "May cause iron deficiency anemia",
                "Hepatic iron oveload may result from copper deficiency induced by therapy",
                "Monitor urinary copper and for signs of hypersensitivity (eg, elevated body temperature) ",
                "Worsening of clinical symptoms, including neurological deterioration, may occur when beginning therapy owing to mobilization of excess stores of copper; adjust dose or discontinue trientine if patientâ€™s clinical condition worsens "
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Mineral supplements",
                        "Avoid coadministration with mineral supplements (eg, iron, zinc, calcium, magnesium) ",
                        "If unavoidable, administer trientine at least 2 hr before or after iron supplements OR at least 1 hr before or 2 hr after other mineral supplements ",
                        "Trientine has potential to chelate non-copper cations in mineral supplements and other oral drugs, and thereby decreasing systemic absorption and efficacy ",
                        "Other oral drugs",
                        "Separate doses by at least 1 hr ",
                        "Trientine may potentially bind other drugs in GI tract and decrease their systemic absorption "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "bendroflumethiazide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bumetanide",
            "description": {
                "common": "bumetanide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "trientine, carbonyl iron.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "chlorothiazide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "chlorthalidone decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "cyclopenthiazide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "ethacrynic acid decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "trientine, ferric maltol.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "trientine, ferrous fumarate.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "trientine, ferrous gluconate.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "trientine, ferrous sulfate.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "furosemide",
            "description": {
                "common": "furosemide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "hydrochlorothiazide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "trientine, iron dextran complex.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "trientine, iron sucrose.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of trientine by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 1hr before the trietine or 1hr after the trientine"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methyclothiazide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "metolazone decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "trientine, polysaccharide iron.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rose hips",
            "description": {
                "common": "trientine, rose hips.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selenium",
            "description": {
                "common": "selenium will decrease the level or effect of trientine by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer trientine at least 1 hr before or after polyvalent cations (2 hr if oral iron administered)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride decreases levels of trientine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer trientine at least 1 hr before and after each dose to avoid chelation with magnesium. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate decreases levels of trientine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer trientine at least 1 hr before and after each dose to avoid chelation with magnesium. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "torsemide decreases levels of trientine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zinc",
            "description": {
                "common": "zinc will decrease the level or effect of trientine by  cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration of trientine and oral polyvalent cation containing products by at least 1 hr."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "copper",
            "description": {
                "common": "trientine decreases levels of copper by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Indicated action (for Wilson's disease)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "19"
        },
        {
            "name": "Change of bowel habits",
            "percent": "15"
        },
        {
            "name": "Rash",
            "percent": "12"
        },
        {
            "name": "Alopecia",
            "percent": "8"
        },
        {
            "name": "Mood swings",
            "percent": "8"
        },
        {
            "name": "Anemia",
            "percent": "4"
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Iron deficiency",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Systemic lupus erythematosus",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Muscle spasms",
            "percent": null
        },
        {
            "name": "rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dystonia",
            "percent": null
        },
        {
            "name": "myasthenia gravis",
            "percent": null
        }
    ]
}